Could a vaccine be the answer to curing pancreatic cancer? A trial at the University of Cincinnati Cancer Center shows promise

It’s the same vaccine technology first used to prevent COVID-19, and it could be the next best treatment for pancreatic cancer patients.

The University of Cincinnati Cancer Center is the first in the Midwest to host this Phase 2 trial, open to pancreatic cancer patients who have not yet started treatment.

In the Phase 1 trial, eight out of 32 patients achieved complete cancer remission, promising a potential shift from the current low cure rates. 

These exciting early results could be game-changing for pancreatic cancer patients across the country, and it is all happening right here at our Cancer Center. #Proud

For more information on the trial, please call 513-584-7698 or email cancer@uchealth.com

PHOTO: Dr. Davendra Sohal, site principal investigator for pancreatic cancer vaccine trial